{"id":"https://openalex.org/W4397007319","doi":"https://doi.org/10.1016/j.esmoop.2024.103235","title":"213P Sequencing antibody-drug conjugates (ADCs) in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (mBC)","display_name":"213P Sequencing antibody-drug conjugates (ADCs) in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (mBC)","publication_year":2024,"publication_date":"2024-05-01","ids":{"openalex":"https://openalex.org/W4397007319","doi":"https://doi.org/10.1016/j.esmoop.2024.103235"},"language":"en","primary_location":{"id":"doi:10.1016/j.esmoop.2024.103235","doi":"https://doi.org/10.1016/j.esmoop.2024.103235","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2024.103235","pdf_url":"http://www.esmoopen.com/article/S2059702924010032/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://www.esmoopen.com/article/S2059702924010032/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052971671","display_name":"Stefania Morganti","orcid":"https://orcid.org/0000-0001-5284-9944","observed_orcids":["https://orcid.org/0000-0001-5284-9944"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Morganti","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081854007","display_name":"Paolo Tarantino","orcid":"https://orcid.org/0000-0001-8686-0228","observed_orcids":["https://orcid.org/0000-0001-8686-0228"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Tarantino","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090301769","display_name":"Noah Graham","orcid":"https://orcid.org/0009-0009-0622-683X","observed_orcids":["https://orcid.org/0009-0009-0622-683X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. Graham","raw_affiliation_strings":["Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015055171","display_name":"Melissa E. Hughes","orcid":"https://orcid.org/0000-0001-6190-9101","observed_orcids":["https://orcid.org/0000-0001-6190-9101"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Hughes","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5096004681","display_name":"Ross J. Kusmick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Kusmick","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076076101","display_name":"Karen Lisa Smith","orcid":"https://orcid.org/0000-0002-6687-0119","observed_orcids":["https://orcid.org/0000-0002-6687-0119"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Smith","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5098677420","display_name":"Georgia L. Suggs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Suggs","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5096259123","display_name":"Molly Skeffington","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Skeffington","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110445203","display_name":"Stefan Buck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Buck","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5095838566","display_name":"Kerry Sendrick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Sendrick","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077190673","display_name":"Abigail Moore","orcid":"https://orcid.org/0000-0001-9546-2942","observed_orcids":["https://orcid.org/0000-0001-9546-2942","https://orcid.org/0009-0005-2761-1746"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Moore","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024995771","display_name":"Ana Christina Garrido-Castro","orcid":"https://orcid.org/0000-0002-5989-6636","observed_orcids":["https://orcid.org/0000-0002-5989-6636"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A.C. Garrido-Castro","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004298689","display_name":"Alessandro Giordano","orcid":"https://orcid.org/0000-0002-6978-0880","observed_orcids":["https://orcid.org/0000-0002-6978-0880","https://orcid.org/0009-0000-6554-1439"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Giordano","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044200630","display_name":"Henrique Afonseca Parsons","orcid":"https://orcid.org/0000-0002-0436-4368","observed_orcids":["https://orcid.org/0000-0002-0436-4368"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H.A. Parsons","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089513581","display_name":"Aleix Prat","orcid":"https://orcid.org/0000-0003-2377-540X","observed_orcids":["https://orcid.org/0000-0003-2377-540X"]},"institutions":[{"id":"https://openalex.org/I4210115097","display_name":"Hospital Cl\u00ednic de Barcelona","ror":"https://ror.org/02a2kzf50","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210115097"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"A. Prat","raw_affiliation_strings":["Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain","institution_ids":["https://openalex.org/I4210115097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062515397","display_name":"Nabihah Tayob","orcid":"https://orcid.org/0000-0001-6088-167X","observed_orcids":["https://orcid.org/0000-0001-6088-167X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. Tayob","raw_affiliation_strings":["Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022319770","display_name":"NU Lin","orcid":"https://orcid.org/0000-0003-2263-5413","observed_orcids":["https://orcid.org/0000-0003-2263-5413"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N.U. Lin","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S.M. Tolaney","raw_affiliation_strings":["Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3730,"currency":"USD","value_usd":3730},"apc_paid":{"value":3730,"currency":"USD","value_usd":3730},"fwci":0.6013,"has_fulltext":true,"cited_by_count":4,"citation_normalized_percentile":{"value":0.61323434,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":97},"biblio":{"volume":"9","issue":null,"first_page":"103235","last_page":"103235"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.5669000148773193,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.5669000148773193,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.1185000017285347,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.10849999636411667,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.996999979019165},{"id":"https://openalex.org/keywords/her2-negative-metastatic-breast-cancer","display_name":"HER2-negative metastatic breast cancer","score":0.9909999966621399},{"id":"https://openalex.org/keywords/treatment-sequencing","display_name":"treatment sequencing","score":0.6700000166893005},{"id":"https://openalex.org/keywords/time-to-next-treatment","display_name":"time to next treatment","score":0.9039999842643738},{"id":"https://openalex.org/keywords/topoisomerase-inhibitors","display_name":"topoisomerase inhibitors","score":0.8059999942779541},{"id":"https://openalex.org/keywords/microtubule-inhibitors","display_name":"microtubule inhibitors","score":0.968999981880188},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.6539999842643738},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.9269999861717224},{"id":"https://openalex.org/keywords/her2-immunohistochemistry","display_name":"HER2 immunohistochemistry","score":0.5429999828338623},{"id":"https://openalex.org/keywords/survival-outcomes","display_name":"survival outcomes","score":0.3089999854564667},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.492000013589859}],"concepts":[{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.8458001613616943},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.6096258163452148},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5889962315559387},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.545953631401062},{"id":"https://openalex.org/C2910363380","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"HER2 negative","level":5,"score":0.5327387452125549},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.5093344449996948},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4974232017993927},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.48104265332221985},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4501035213470459},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4363408088684082},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42431509494781494},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4207620620727539},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3953320384025574},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3327735662460327},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.19635054469108582},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.15339812636375427},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.esmoop.2024.103235","doi":"https://doi.org/10.1016/j.esmoop.2024.103235","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2024.103235","pdf_url":"http://www.esmoopen.com/article/S2059702924010032/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.esmoop.2024.103235","doi":"https://doi.org/10.1016/j.esmoop.2024.103235","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2024.103235","pdf_url":"http://www.esmoopen.com/article/S2059702924010032/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4397007319.pdf","grobid_xml":"https://content.openalex.org/works/W4397007319.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4409196689","https://openalex.org/W7162669469","https://openalex.org/W4411287287","https://openalex.org/W4379285866","https://openalex.org/W4410804446","https://openalex.org/W4409451455","https://openalex.org/W4411289390","https://openalex.org/W7129310242","https://openalex.org/W4417142542","https://openalex.org/W4415940208"],"abstract_inverted_index":{"ADCs":[0,28,41,89,94],"are":[1],"effective":[2],"for":[3,68,70,79,102,106,173,217,229,300,305,308],"pts":[4,21,85,145,157,188,237,243,355],"with":[5,22,368],"HER2-":[6,23],"MBC":[7,24,135,174,185,320],"but":[8],"little":[9],"is":[10,378],"known":[11],"about":[12],"sequencing":[13],"of":[14,116,129,166,170,208,235,249,373],"different":[15,276],"ADCs.":[16,256],"We":[17,60,125],"analyzed":[18],"data":[19,289],"from":[20,198,203,290],"who":[25,86],"received":[26,87,356],"\u22652":[27],"and":[29,50,78,154,183,195,231,264,286,302,360,370],"had":[30,147,158,238,244],"\u22656":[31],"months":[32],"(mo)":[33],"follow-up":[34],"at":[35,112,121,134],"Dana-Farber":[36],"Cancer":[37],"Institute":[38],"between":[39,84,93,193,255],"6/2014-1/2023.":[40],"were":[42],"grouped":[43],"based":[44],"on":[45],"targets":[46],"(HER2,":[47],"Trop2,":[48],"other)":[49],"payloads":[51],"(topoisomerase":[52],"inhibitor":[53,57],"\u2013":[54],"TOPi;":[55],"microtubule":[56],"-":[58],"MI).":[59],"determined":[61],"time":[62],"to":[63,100,178,180,200,205,381],"next":[64],"treatment":[65],"(tx)":[66],"(TTNT)":[67],"ADC1,":[69],"the":[71,269],"tx":[72,92,104,247,277,383],"given":[73,176],"immediately":[74],"after":[75],"ADC1":[76,113,117,122,142,179,194,209,230,301,359,369],"(postADC1),":[77],"ADC2.":[80,232,363],"TTNT-postADC1":[81,258],"was":[82,137,175,259,271,366],"compared":[83],"consecutive":[88,239],"or":[90,274],"intervening":[91,246],"using":[95],"an":[96],"inverse":[97],"probability":[98],"weighting":[99],"account":[101],"non-randomized":[103],"(adjustment":[105],"hormone":[107],"receptor":[108,374],"(HR)/HER2":[109],"IHC":[110,191],"status":[111,192],"start,":[114,118,123,143],"year":[115],"visceral":[119],"disease":[120],"TTNT-ADC1).":[124],"identified":[126],"a":[127,275,348],"total":[128,234],"62":[130],"pts.":[131,186],"Median":[132,257],"age":[133],"diagnosis":[136],"51":[138],"(41-58)":[139],"years.":[140],"At":[141],"29":[144],"(47%)":[146],"triple":[148],"negative":[149],"(TN)":[150],"(17":[151],"HER2":[152,161,190],"low)":[153,162],"33":[155],"(53%)":[156],"HR+":[159,184],"(21":[160],"MBC.":[163],"A":[164,233],"median":[165],"1":[167,250],"(0-5)":[168],"line":[169],"chemotherapy":[171],"(CT)":[172],"prior":[177],"both":[181],"TN":[182],"Seven":[187],"switched":[189],"ADC2":[196],"(3":[197],"0":[199],"low,":[201],"4":[202],"low":[204],"0).":[206],"Distribution":[207],"was:":[210],"64%":[211],"antiTrop2-TOPi,":[212,222],"23%":[213],"antiHER2-TOPi,":[214,220],"13%":[215],"nonHER2/nonTrop2-MI;":[216],"ADC2:":[218],"66%":[219],"31%":[221],"3%":[223],"nonHER2/nonTrop2-MI.":[224],"The":[225],"table":[226,346],"reports":[227],"TTNT":[228,299,304,307,365],"26":[236],"ADCs,":[240],"while":[241],"36":[242],"1-5":[245],"(median":[248],"CT":[251],"line,":[252],"range":[253],"0-5)":[254],"4.37":[260],"mo":[261,312,316,323,327,333,337,344],"(95%CI":[262],"3.12-4.89)":[263],"did":[265],"not":[266],"differ":[267],"if":[268],"postADC1":[270],"another":[272],"ADC":[273],"(HR":[278],"0.89,":[279],"95%":[280],"CI":[281,314,318,325,329,335,339],"0.43-1.87,":[282],"p=0.76).":[283],"Genomic":[284],"features":[285],"gene":[287],"expression":[288],"circulating":[291],"tumor":[292],"DNA":[293],"(DNADX)":[294],"will":[295],"be":[296],"presented.Table:":[297],"213PMedian":[298],"ADC2Median":[303],"ADC1Median":[306],"ADC2Overall":[309],"population":[310],"(n=62)4.34":[311],"(95%":[313,317,324,328,334,338],"3.68-5.52)5.39":[315],"3.91-8.38)HR+":[319],"(n=33,":[321],"53%)4.66":[322],"3.09-5.75)5.62":[326],"3.91-NA)TNBC":[330],"(n=29,":[331],"47%)4.11":[332],"3.68-6.87)5.29":[336],"2.66-NA)Median":[340],"follow":[341],"up:":[342],"23.1":[343],"Open":[345],"in":[347],"new":[349],"tab":[350],"In":[351],"this":[352],"cohort,":[353],"most":[354],"antiTrop2":[357],"as":[358,362],"antiHER2":[361],"Similar":[364],"observed":[367],"ADC2,":[371],"irrespective":[372],"status.":[375],"Ongoing":[376],"work":[377],"investigating":[379],"biomarkers":[380],"guide":[382],"sequencing.":[384]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2024-05-18T00:00:00"}